Primecap Management Co. CA Has $4.37 Million Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Primecap Management Co. CA trimmed its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 20.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 232,000 shares of the company’s stock after selling 58,000 shares during the quarter. Primecap Management Co. CA owned about 0.31% of Nurix Therapeutics worth $4,371,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. US Bancorp DE increased its holdings in shares of Nurix Therapeutics by 144.7% during the 4th quarter. US Bancorp DE now owns 1,424 shares of the company’s stock valued at $27,000 after acquiring an additional 842 shares during the last quarter. Quarry LP raised its position in shares of Nurix Therapeutics by 3,746.2% in the third quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $56,000 after purchasing an additional 2,435 shares during the period. Quest Partners LLC raised its position in shares of Nurix Therapeutics by 21.3% in the third quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after purchasing an additional 1,312 shares during the period. Bellevue Group AG bought a new stake in shares of Nurix Therapeutics during the 3rd quarter worth $180,000. Finally, EP Wealth Advisors LLC acquired a new position in Nurix Therapeutics in the 3rd quarter valued at $240,000.

Insider Activity

In other news, insider Gwenn Hansen sold 3,690 shares of the firm’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the sale, the insider now directly owns 55,937 shares in the company, valued at approximately $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Houte Hans Van sold 2,811 shares of the company’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $55,798.35. Following the transaction, the chief financial officer now owns 39,549 shares in the company, valued at approximately $785,047.65. This trade represents a 6.64 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 12,326 shares of company stock worth $213,449. Insiders own 7.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on NRIX shares. Leerink Partners initiated coverage on shares of Nurix Therapeutics in a research report on Monday. They set a “market perform” rating and a $16.00 target price for the company. BMO Capital Markets started coverage on Nurix Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $35.00 price objective for the company. HC Wainwright raised their target price on Nurix Therapeutics from $35.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. cut their price target on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Finally, Morgan Stanley raised their price objective on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the stock an “equal weight” rating in a research note on Monday, February 3rd. Three analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $30.88.

Nurix Therapeutics Price Performance

Shares of NASDAQ:NRIX opened at $13.90 on Thursday. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -4.81 and a beta of 2.18. The business’s fifty day moving average price is $17.22 and its two-hundred day moving average price is $20.93. Nurix Therapeutics, Inc. has a fifty-two week low of $11.90 and a fifty-two week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. Research analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.